Cervical Cancer & HPV

The American Cancer Society reports that an estimated 11,270 cases of invasive cervical cancer are expected to be diagnosed in 2009, with 4,070 estimated deaths. When cervical cancer is found in its early stages, it can often be cured.

The Pap smear is a standard screening test to check for cervical cell changes that might become cervical cancer if left untreated. Abnormalities found in cervical cells are generally a sign of the presence of human papillomavirus (HPV), a sexually transmitted virus that affects an estimated 70% of all sexually active people at some time in their lives.

There are certain types of HPV that are associated with cancer and are divided into “low risk” and “high risk” groups. HPV testing can be performed to determine of the virus is present, complemented with HPV genotyping to establish the strain of the virus. Knowing the HPV strain can aid the physician in the management of the virus, as persisting infections are more likely to progress to form high grade lesions that are the precursors to cervical cancer.

Gynecor provides HPV genotyping as a standalone test, as well as a complement to the TruTest endometrial brush biopsy. Additionally, HPV genotyping can be performed from the a Liquid-based Pap test or can be added on to Gynecor's Colposcopy.

These tests provide the physician with data that is useful when weighing treatment options in the management of cervical health.

Please visit our Patient Resources section to find additional information related to cervical cancer.